Table 3.

Characteristics associated with flare following discontinuation of TKI

Clinical characteristicNumber% flareP
Exon 19 deletion4122%1
Exon 21 L858R1921%
T790M3318%0.5
No T790M1926%
First-line TKI alone2934%0.06
First-line chemo3213%
TKI only2030%0.5
Chemo4120%
Symptoms of disease progression2040%0.05
No symptoms4115%
Karnofsky performance status 70%1136%0.4
Karnofsky performance status 80%–90%5022%
CNS involvement1450%0.01
No CNS disease4715%
Bone involvement3126%0.8
No bony disease3020%
Pleural involvement3633%0.03
No pleural disease258%
Male1315%0.7
Female4825%
Erlotinib4033%0.3
Gefitinib119%
Current/former smoker1216%0.7
Never smoker4924%